Retinoblastoma and mosaic 13q deletion: a case report.

13q-syndrome Cytogenetics Molecular genetics Mosaicism Retinoblastoma

Journal

International journal of retina and vitreous
ISSN: 2056-9920
Titre abrégé: Int J Retina Vitreous
Pays: England
ID NLM: 101677897

Informations de publication

Date de publication:
03 Sep 2021
Historique:
received: 25 01 2021
accepted: 26 08 2021
entrez: 4 9 2021
pubmed: 5 9 2021
medline: 5 9 2021
Statut: epublish

Résumé

Patients with 13q-syndrome are at risk of retinoblastoma when the RB1 gene, located in the chromosomal band 13q14.2, is deleted. This syndrome is frequently associated with congenital malformations and developmental delay, although these signs could be mild. Mosaic 13q-deletion patients have been previously reported in the literature; their phenotype is variable, and they may not be recognized. Retinoblastoma diagnosed in a child with 13q-mosaicism confirmed in blood, oral mucosa, healthy retina and retinoblastoma. A second RB1 hit is present exclusively in the retinoblastoma sample (RB1 c.958C>T p.Arg320Ter). Other detected molecular events in retinoblastoma are 6p12.3pter gain and 6q25.3qter loss. Clinical examination is unremarkable except for clinodactyly of the right fifth finger. We describe a case of mosaic 13q deletion syndrome affected by retinoblastoma. Molecular data obtained from the tumor analysis are similar to previous data available about this malignancy. High clinical suspicion is essential for an adequate diagnosis of mosaic cases.

Sections du résumé

BACKGROUND BACKGROUND
Patients with 13q-syndrome are at risk of retinoblastoma when the RB1 gene, located in the chromosomal band 13q14.2, is deleted. This syndrome is frequently associated with congenital malformations and developmental delay, although these signs could be mild. Mosaic 13q-deletion patients have been previously reported in the literature; their phenotype is variable, and they may not be recognized.
CASE PRESENTATION METHODS
Retinoblastoma diagnosed in a child with 13q-mosaicism confirmed in blood, oral mucosa, healthy retina and retinoblastoma. A second RB1 hit is present exclusively in the retinoblastoma sample (RB1 c.958C>T p.Arg320Ter). Other detected molecular events in retinoblastoma are 6p12.3pter gain and 6q25.3qter loss. Clinical examination is unremarkable except for clinodactyly of the right fifth finger.
DISCUSSION AND CONCLUSIONS CONCLUSIONS
We describe a case of mosaic 13q deletion syndrome affected by retinoblastoma. Molecular data obtained from the tumor analysis are similar to previous data available about this malignancy. High clinical suspicion is essential for an adequate diagnosis of mosaic cases.

Identifiants

pubmed: 34479642
doi: 10.1186/s40942-021-00321-9
pii: 10.1186/s40942-021-00321-9
pmc: PMC8418035
doi:

Types de publication

Journal Article

Langues

eng

Pagination

50

Subventions

Organisme : Fundación para la Investigación del Hospital Universitari La Fe
ID : XVIII edition post-resident awards

Informations de copyright

© 2021. The Author(s).

Références

Hum Genet. 1983;64(2):160-2
pubmed: 6885051
Sci Rep. 2016 Apr 29;6:25264
pubmed: 27126562
Lancet Oncol. 2013 Apr;14(4):327-34
pubmed: 23498719
Nature. 2012 Jan 11;481(7381):329-34
pubmed: 22237022
Front Genet. 2018 May 17;9:170
pubmed: 29868118
Nature. 1995 Dec 21-28;378(6559):789-92
pubmed: 8524414
Genes Chromosomes Cancer. 1996 Apr;15(4):223-33
pubmed: 8703848
Genet Couns. 2015;26(2):213-7
pubmed: 26349191
Hum Genet. 2001 Feb;108(2):98-104
pubmed: 11281459
Ultrasound Obstet Gynecol. 2002 Apr;19(4):396-9
pubmed: 11952971
Nat Rev Dis Primers. 2015 Aug 27;1:15021
pubmed: 27189421
PLoS One. 2016 Apr 26;11(4):e0153323
pubmed: 27115612
Am J Hum Genet. 1969 Sep;21(5):499-512
pubmed: 5347076
Yan Ke Xue Bao. 1989 Jun;5(1-2):7-13
pubmed: 2485748
Am J Hum Genet. 1995 Oct;57(4):859-66
pubmed: 7573047
Br J Cancer. 1992 Jul;66(1):211-9
pubmed: 1637670
Clin Cancer Res. 2017 Jul 1;23(13):e98-e106
pubmed: 28674118
Mol Cytogenet. 2018 Sep 19;11:53
pubmed: 30250511
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
Oncotarget. 2014 Jan 30;5(2):438-50
pubmed: 24509483
Eur J Hum Genet. 2011 Sep;19(9):947-58
pubmed: 21505449

Auteurs

Pablo Gargallo (P)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain. pablogt28@gmail.com.
Oncology Department, Imegen-Health in Code Group, Valencia, Spain. pablogt28@gmail.com.

Silvestre Oltra (S)

Genetics Unit, La Fe Hospital, Valencia, Spain.
Genetics Department, Valencia University, Valencia, Spain.

Julia Balaguer (J)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.
Oncology Department, Imegen-Health in Code Group, Valencia, Spain.
Genetics Unit, La Fe Hospital, Valencia, Spain.
Genetics Department, Valencia University, Valencia, Spain.
Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain.

Honorio Barranco (H)

Pediatric Ophthalmology Unit, University Hospital La Fe Hospital, Valencia, Spain.

Yania Yáñez (Y)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.

Vanessa Segura (V)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.

Antonio Juan-Ribelles (A)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.
Oncology Department, Imegen-Health in Code Group, Valencia, Spain.
Genetics Unit, La Fe Hospital, Valencia, Spain.
Genetics Department, Valencia University, Valencia, Spain.
Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain.

Inés Calabria (I)

Oncology Department, Imegen-Health in Code Group, Valencia, Spain.

Margarita Llavador (M)

Pathology Department, University La Fe Hospital, Valencia, Spain.

Victoria Castel (V)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.

Adela Cañete (A)

Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.
Oncology Department, Imegen-Health in Code Group, Valencia, Spain.
Genetics Unit, La Fe Hospital, Valencia, Spain.
Genetics Department, Valencia University, Valencia, Spain.
Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain.

Classifications MeSH